Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 15/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.71 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL71180 | 1.00 | OPRD1 (0.71) | OPRD1KCNH2OPRM1MEN1KMT2A | |
| SCHEMBL71181 | 1.00 | OPRD1 (0.71) | OPRD1KCNH2OPRM1MEN1KMT2A | |
| SCHEMBL73453 | 1.00 | OPRD1 (0.71) | OPRD1KCNH2OPRM1MEN1KMT2A | |
| SCHEMBL72787 | 0.92 | OPRD1 (0.64) | OPRD1KCNH2OPRM1OPRK1 | |
| SCHEMBL72775 | 0.92 | OPRD1 (0.64) | OPRD1KCNH2OPRM1OPRK1 | |
| SCHEMBL12569760 | 0.92 | OPRD1 (0.66) | OPRD1KCNH2OPRM1OPRK1 | |
| SCHEMBL84143 | 0.92 | OPRD1 (0.66) | OPRD1KCNH2OPRM1OPRK1 | |
| SCHEMBL9925787 | 0.90 | OPRD1 (0.72) | OPRD1KCNH2OPRM1MEN1KMT2A | |
| SCHEMBL84149 | 0.90 | OPRD1 (0.72) | OPRD1KCNH2OPRM1MEN1KMT2A | |
| SCHEMBL12569764 | 0.86 | OPRD1 (0.65) | OPRD1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629363-B2 | Prophylaxis and treatment of angioedema | PHARVARIS GMBH (CH) | 2026-05-19 | — | — | US | claimed |
| US-20250339483-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON INTRANASAL ADMINISTRATION, AND USES THEREOF | AGS THERAPEUTICS SAS (FR) | 2025-11-06 | — | — | US | claimed |
| EP-4608424-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON INTRANASAL ADMINISTRATION, AND USES THEREOF | AGS Therapeutics SAS (FR) | 2025-09-03 | — | — | EP | claimed |
| US-20240325404-A1 | TREATMENT OF INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2024-10-03 | — | — | US | claimed |
| EP-4370128-A1 | TREATMENT OF INFLAMMATORY DISEASES | Galapagos N.V. (BE) | 2024-05-22 | — | — | EP | claimed |
| WO-2024088808-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON INTRANASAL ADMINISTRATION, AND USES THEREOF | AGS THERAPEUTICS SAS (FR) | 2024-05-02 | — | — | WO | claimed |
| CN-117677387-A | Treatment of inflammatory diseases | 加拉帕戈斯股份有限公司 | 2024-03-08 | — | — | CN | claimed |
| WO-2023161326-A1 | COMPOUND FOR USE IN AND METHODS OF TREATMENT OF INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2023-08-31 | — | — | WO | claimed |
| WO-2023285405-A1 | TREATMENT OF INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2023-01-19 | — | — | WO | claimed |
| US-12629363-B2 | Prophylaxis and treatment of angioedema | PHARVARIS GMBH (CH) | 2026-05-19 | — | — | US | disclosed |
| WO-2026098666-A1 | COCRYSTAL OF TYK2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 杭州领业医药科技有限公司 | 2026-05-15 | — | — | WO | disclosed |
| US-20260060822-A1 | BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4243824-B1 | PROPHYLAXIS AND TREATMENT OF ANGIOEDEMA | PHARVARIS GMBH (CH) | 2025-12-24 | — | — | EP | disclosed |
| US-20250366979-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | METHODIST HOSPITAL (US) | 2025-12-04 | — | — | US | disclosed |
| WO-2023285405-A1 | TREATMENT OF INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2023-01-19 | — | — | WO | disclosed |
| WO-2022204802-A1 | USE OF PSYCHEDELICS TO TREAT DEMENTIA | MYND LIFE SCIENCES INC. (CA) | 2022-10-06 | — | — | WO | disclosed |
| WO-2022101395-A1 | PROPHYLAXIS AND TREATMENT OF ANGIOEDEMA | PHARVARIS GMBH (CH) | 2022-05-19 | — | — | WO | disclosed |
| US-20220135564-A1 | DEUTERATED MITRAGYNINE ANALOGS AS SAFER OPIOID MODULATORS IN THE MITRAGYNINE CLASS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-05-05 | — | — | US | disclosed |
| WO-2022074588-A1 | CARBOXYLIC DIARYLTHIAZEPINEAMINES AND USES THEREFOR | KURES, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022074589-A1 | CARBOXYLIC DIARYLTHIAZEPINEAMINES AND USES THEREFOR | KURES, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339483-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON INTRANASAL ADMINISTRATION, AND USES THEREOF | NLN, DCX, CNTN1 | OPRD1 980/4885KCNH2 2720/4885OPRM1 695/4885 |
| US-20240325404-A1 | TREATMENT OF INFLAMMATORY DISEASES | IFNAR1, IFNG, IRF3 | OPRD1 1366/4885KCNH2 4625/4885OPRM1 1974/4885 |
| US-20260060822-A1 | BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF | PFKP, PBK, MYLK | OPRD1 4518/4885KCNH2 2799/4885OPRM1 4810/4885 |
| US-20220135564-A1 | DEUTERATED MITRAGYNINE ANALOGS AS SAFER OPIOID MODULATORS IN THE MITRAGYNINE CLASS | OPRD1, OPRK1, OPRM1 | OPRD1 1/4885KCNH2 1403/4885OPRM1 3/4885 |
| US-12629363-B2 | Prophylaxis and treatment of angioedema | BDKRB2, BDKRB1, HRH2 | OPRD1 2223/4885KCNH2 176/4885OPRM1 2163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.